Search Result

Results for "

tumor vasculature

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Apoptosis (3) Biochemical Assay Reagents (3) c-Kit (3) c-Met/HGFR (3) CD73 (1) E-Selectin (1) FLT3 (3) Liposome (4) Microtubule/Tubulin (1) Peptide-Drug Conjugates (PDCs) (1) Reference Standards (1) TAM Receptor (3) Tie (1) VEGFR (3)
By Research Areas:	Cancer (16) Cardiovascular Disease (4) Metabolic Disease (1)
Oligonucleotides:	Pegylated Lipids (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Oligonucleotides

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P991384

DX-2240	Tie	Cancer
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .

HY-P10770

P-ESBP-DOX	Peptide-Drug Conjugates (PDCs) E-Selectin	Cardiovascular Disease Cancer
P-ESBP-DOX is a HPMA copolymer-drug conjugate, which is consistituted of the E-selectin binding peptide and the Doxorubicin (HY-15142). P-ESBP-DOX exhibits cytotoxicity against TNFα-activated human vascular endothelial cells IVECs with an IC₅₀ of 0.28 μM. P-ESBP-DOX can be used in research about tumor vasculature .

HY-161248

E7130	Microtubule/Tubulin	Cancer
E7130 is a microtubule inhibitor, which ameliorates the tumor microenvironment through suppression of cancer-associated fibroblasts (CAF) and promotion of tumor vasculature remodeling .

HY-P10705

KGFRWR	Biochemical Assay Reagents	Cancer
KGFRWR is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. KGFRWR can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P991330

BMS-986179	CD73	Cancer
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .

HY-P10709

CREKA peptide	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P10709A

CREKA peptide acetate	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-172497

DSPE-PEG2000-Mal-Cys-REKA	Liposome	Cancer
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-Mal-Cys-REKA	Liposome	Cancer
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-Mal-Cys-REKA	Liposome	Cancer
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-Mal-Cys-REKA	Liposome	Cancer
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-13016A

Cabozantinib hydrochloride XL184 hydrochloride; BMS-907351 hydrochloride	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib hydrochloride is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035 and 1.3 nM, respectively. Cabozantinib hydrochloride displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib hydrochloride shows antiangiogenic activity. Cabozantinib hydrochloride disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-13016

Cabozantinib Maximum Cited Publications 49 Publications Verification XL184; BMS-907351	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-103211

L748337 1 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Cancer
L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over β1 and β2 receptors. The K_i values of L748337 for β3-, β2- and β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively . L748337 couples predominantly to G_i to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC₅₀ value of 11.6 . L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases .

HY-13016R

Cabozantinib (Standard) XL184 (Standard); BMS-907351 (Standard)	Reference Standards VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

Cat. No.	Product Name	Type

HY-172497

DSPE-PEG2000-Mal-Cys-REKA	Drug Delivery
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-Mal-Cys-REKA	Drug Delivery
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-Mal-Cys-REKA	Drug Delivery
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-Mal-Cys-REKA	Drug Delivery
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P10770

P-ESBP-DOX	Peptide-Drug Conjugates (PDCs) E-Selectin	Cardiovascular Disease Cancer
P-ESBP-DOX is a HPMA copolymer-drug conjugate, which is consistituted of the E-selectin binding peptide and the Doxorubicin (HY-15142). P-ESBP-DOX exhibits cytotoxicity against TNFα-activated human vascular endothelial cells IVECs with an IC₅₀ of 0.28 μM. P-ESBP-DOX can be used in research about tumor vasculature .

HY-P10705

KGFRWR	Biochemical Assay Reagents	Cancer
KGFRWR is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. KGFRWR can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P10709

CREKA peptide	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

HY-P10709A

CREKA peptide acetate	Biochemical Assay Reagents	Cardiovascular Disease Cancer
CREKA peptide acetate is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide acetate can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity .

Cat. No.	Product Name	Target	Research Area

HY-P99279

Bavituximab Anti-Human Phosphatidylserine Recombinant Antibody	Inhibitory Antibodies	Cancer
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .

HY-P991384

DX-2240	Tie	Cancer
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .

HY-P991330

BMS-986179	CD73	Cancer
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .

Cat. No.	Product Name		Classification

HY-172497

DSPE-PEG2000-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-Mal-Cys-REKA		Pegylated Lipids
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.